Shares of Qiagen QGEN moved higher in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 41.67% year over year to $0.68, which beat the estimate of $0.65.
Revenue of $571,234,000 higher by 38.16% year over year, which beat the estimate of $548,860,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Qiagen hasn't issued any revenue guidance for the time being.
Price Action
Company's 52-week high was at $59.00
52-week low: $34.77
Price action over last quarter: Up 18.09%
Company Description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (47%), followed by EMEA (32%) and Asia-Pacific (21%).
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.